Cytosorbents Corporation (CTSO) is a Medical - Devices company in the Healthcare sector, currently trading at $0.59. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Valuation: CTSO trades at a trailing Price-to-Earnings (P/E) of -4.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Financials: revenue is $37M, +8.6%/yr average growth. Net income is $8M (loss), growing at +33.6%/yr. Net profit margin is -22.1% (negative). Gross margin is 71.5% (+19 pp trend).
Balance sheet: total debt is $29M against $6M equity (Debt-to-Equity (D/E) ratio 4.93, leveraged). Current ratio is 2.13 (strong liquidity). Debt-to-assets is 65.9%. Total assets: $44M.
Analyst outlook: 12 / 13 analysts rate CTSO as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
